Evidence map›Paper›PMID 41376953›Full record

ArticleJournal of thoracic disease2025

Avoiding the toll of lung injury while driving CAR T cells to the target tumor.

Victoria Cranwell, Prasad S Adusumilli, Meriem Taleb

Abstract readEditorialComment
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Victoria CranwellThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Prasad S AdusumilliThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Meriem TalebThoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
SURGICAL ONCOLOGY RESEARCH TRAINING PROGRAMT32CA009501 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Babak J Mehrara · 1985 to 2026
$7.7M
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesotheliomaR01CA235667 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S. · 2019 to 2024
$3.6M
Tuning KITv CAR T cells for the solid tumor environmentR01CA292664 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Prasad S. Adusumilli · 2024 to 2026
$3.2M
CD28-KITv CAR T cells with PD-1 dominant negative receptorUG3CA290241 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S. · 2024 to 2025
$3.1M
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumorsR01CA236615 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ADUSUMILLI, PRASAD S., SOLOMON, STEPHEN BARNETT · 2018 to 2022
$2.0M
NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA235667NCI NIH HHS R01 CA236615NCI NIH HHS R01 CA292664NCI NIH HHS T32 CA009501NCI NIH HHS UG3 CA290241
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CAR T-cell therapyon-target off-tumor toxicitypulmonary toxicity

Identifiers

PMID41376953
PMCPMC12688607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.